Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. The company is headquartered in New York City, New York and currently employs 2 full-time employees. The company went IPO on 2019-02-15. The firm is focused on developing a topical formulation for treating side effects from drugs used for the treatment of cancer (HT-001); a treatment for mast-cell derived cancers and anaphylaxis (HT-KIT), and a treatment and/or prevention for Alzheimer's or other neuroinflammatory diseases (HT-ALZ). The firm also has assets being developed for atopic dermatitis (also known as eczema) (BioLexa); a treatment for asthma and allergies using inhalational administration (HT-004), and a treatment for obesity, and obesity-related diseases and conditions (HT-VA).
Hoth Therapeutics Inc 주요 수익원은 Artificial Intelligence-Enabled Digital Manufacturing Marketplace이며, 최신 수익 발표에서 수익은 545,529,000입니다. 지역별로는 United States이 Hoth Therapeutics Inc의 주요 시장이며, 수익은 456,727,000입니다.
Hoth Therapeutics Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 Hoth Therapeutics Inc의 순손실은 $-8입니다.